OncoMatch/Clinical Trials/NCT07203352
Efficacy of Targeted Drugs Combined With Chemotherapy in the Treatment of T-ALL
Is NCT07203352 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies targeted drug for acute lymphoblastic leukemia.
Treatment: targeted drug — This prospective, randomized, controlled trial evaluates the efficacy and safety of a new targeted drug combined with chemotherapy versus standard chemotherapy alone. Eligible patients were randomized 1:1 to either the treatment or control group.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: systemic or local anti-leukemia treatment including chemotherapy
Previously received systemic or local treatments including chemotherapy
Cannot have received: hematopoietic stem cell transplantation
Previously underwent hematopoietic stem cell transplantation
Lab requirements
Kidney function
creatinine level higher than 1.5 times the upper limit of normal (unless caused by leukemia)
Liver function
ALT or AST higher than twice the upper limit of normal, AKP and bilirubin higher than 1.5 times the upper limit of normal (unless caused by leukemia)
Cardiac function
Left ventricular ejection fraction ≤ 50%
ALT or AST higher than twice the upper limit of normal, AKP and bilirubin higher than 1.5 times the upper limit of normal, creatinine level higher than 1.5 times the upper limit of normal; Left ventricular ejection fraction ≤ 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify